Plasma homocysteine and cysteine levels in retinal vein occlusion

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 4067-4071

  Pinna, Antonio ^a   Carru, Ciriaco ^a   Zinellu, Angelo ^a   Dore, Stefano ^a   Deiana, Luca ^a   Carta, Francesco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CENTRAL RETINA VEIN OCCLUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; STUDENT T TEST; BLOOD; METHODOLOGY; MIDDLE AGED; RETINA VEIN OCCLUSION;

AGED; CASE-CONTROL STUDIES; CYSTEINE; ELECTROPHORESIS, CAPILLARY; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION;

EID: 33749138005     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0290     Document Type: Article

References (40)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
3. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84:154-157.
4. Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye. 2000;14:590-593.
5. Vine AK. Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2000;98:493-503.
6. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemostasis. 2001;86:772-776.
7. Brown BA, Marx JL, Ward PT, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology. 2002;109:287-290.
8. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol. 2002;12:495-500.
9. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocysteinemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:286-290.
10. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocysteinemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology. 2002;109:1105-1109.
11. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136-1150.
12. Yildirim C, Yaylali V, Tatlipinar S, Kaptanoglu B, Akpinar S. Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica. 2004;218:102-106.
13. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol. 2005;139:181-182.
14. Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina. 2006;26:65-70.
15. Jacob N, Bruckert E, Giral P, et al. Cysteine is a cardiovascular risk factor in hyperlipidemic patients. Atherosclerosis. 1999;146:53-59.
16. El-Khairy L, Ueland PM, Refsum H, et al. Plasma total cysteine as a risk factor for vascular disease. Circulation. 2001;103:2544-2549.
17. Zinellu A, Carru C, Galistu F, et al. N-methyl-D-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis. 2003;24:2796-2804.
18. McGimpsey SJ, Woodside JV, Bamford L, et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci. 2005;46:4712-4716.
19. Rodriguez JJ, Santolaria F, Martinez-Riera A, et al. Clinical significance of homocysteine in elderly hospitalized patients. Metabolism. 2006;55:620-627.
20. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1:228-237.
21. Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central vein occlusion. Acta Ophthalmol Scand. 2000;78:340-343.
22. Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 2000;107:1588-1592.
23. Boyd S, Owens D, Gin T, et al. Plasma homocysteine, methylenetetrahydrofolate reductase C677T and factor II G20210A polymorphism, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001;85:1313-1315.
24. Di Crecchio L, Battaglia Parodi M, Sanguinetti G, Iacono P, Ravalico G. Hyperhomocysteinemia, and the methylenetetrahydrofolate reductase C677T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology. 2004;111:940-945.
25. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr. 1998;67:263-270.
26. Refsum H, Fiskerstrand T, Guttormsen AB, Ueland PM. Assessment of homocysteine status. J Inherit Metab Dis. 1997;20:286-294.
27. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem. 1995;41:340-342.
28. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1-30.
29. Nishiuch Y, Sasaki M, Nakayasu M, et al. Cytotoxicity of cysteine in culture media. In Vitro. 1976;12:635-638.
30. Dudman NP, Hicks C, Wang J, et al. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis. 1991;91:77-83.
31. Saez G, Thornalley PJ, Hill HA, et al. The production of free radicals during the autoxidation of cysteine and their effect on isolated rat hepatocytes. Biochim Biophys Acta. 1982;719:24-31.
32. Lakshminarayanan V, Lewallen M, Frangogiannis NG, et al. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol. 2001;159:1301-1311.
33. Heinecke JW, Rosen H, Suzuki LA, et al. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem. 1987;262:10098-10103.
34. Hogg N. The effect of cysteine on the auto-oxidation of homocysteine. Free Radic Biol Med. 1999;27:28-33.
35. Welch GN, Upchurch GR, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract. 1997;32:81-92.
36. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed endothelial cell injury from homocysteine. J Clin Invest. 1986;77:1370-1376.
37. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
38. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996;143:845-849.
39. Araki A, Sako Y, Fukushima Y, et al. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989;79:139-146.
40. Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol. 1995;15:232-240.